Granted Patent
B2
US 12,644,124 · App. 19/230,651 · Granted Jun 2, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.
Claims (2)
1 . A composition that comprises a recombinant plasmid (RP) that comprises a sequence of nucleotides that is SEQ ID NO 14.
2 . The composition of claim 1 , wherein the RP is encapsulated in: a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 25, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072112/0908 →
Continuity (3)
References Cited (47)
CA 2721333A1
· 2009
[cited by applicant]
Van den Berg, et al., pp. 1-12, Molecular Therapy—Nucleic Acids, vol. 5, 2016 (Year: 2016).
[cited by examiner]
Denzler R et al., Mol Cell. Nov. 3, 2016;64(3):565-579 (Year: 2016).
[cited by examiner]
Ying et al. 2008. Mol. Biotechnol. 38:257-268 (Year: 2008).
[cited by examiner]
Lam et al. 2015. Molec. Ther. Nuc. Ac. 4:e252 (Year: 2015).
[cited by examiner]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Denzler et al. “Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression.” Molecular cell 64.3 (2016): 565-579.
[cited by applicant]
Van Den Berg et al. “Design of effective primary microRNA mimics with different basal stem conformations.” Molecular Therapy Nucleic Acids 5 (2016).
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
Ying et al. “The microRNA (miRNA): overview of the RNA genes that modulate gene function.” Molecular biotechnology 38 (2008): 257-268.
[cited by applicant]
Lam et al. “siRNA versus miRNA as therapeutics for gene silencing.” Molecular therapy Nucleic acids 4 (2015).
[cited by applicant]
Zuo et al. “5—Hydroxytryptamine receptor 1D aggravates hepatocellular carcinoma progression through FoxO6 in AKT—dependent and independent manners.” Hepatology 69.5 (2019): 2031-2047.
[cited by applicant]
Volpicelli et al. “The micro RNA-29A modulates 5-HTR7 expression and its morphogenic effects in hippocampal neurons.” (2019).
[cited by applicant]
[cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112.
[cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023).
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
[cited by applicant]
Lundstrom K., Viruses. Mar. 7, 2023;15(3):698 (Year: 2023).
[cited by applicant]
GenBank EGF Sequence (2023).
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016.
[cited by applicant]
NCBI search results for Seq ID No. 5 (2024).
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
GenBank EGFR Sequence (2023).
[cited by applicant]
Genbank FLT3 Sequence (2024).
[cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024).
[cited by applicant]
Kenji and Mizukami < star-protocols.cell.com/protocols/3185 >, Dec. 15, 2023, 17 pages, accessed on Sep. 9, 20225 (Year: 2023).
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery”. Nat Rev Drug Discov. May 2019; 18(5):358-378. (Year: 2019).
[cited by applicant]
Yang et al., Journal of Neuroimmunology, vol. 178, Issues 1-2, 2006, pp. 24-29, ISSN 0165-5728 (Year: 2006).
[cited by applicant]
Millan, Current Opinion in Pharmacology, vol. 11, Issue 1, 2011, pp. 11-22, ISSN 1471-4892 (Year: 2011).
[cited by applicant]
Francois (Journal of Neuroscience Sep. 19, 2018, 38 (38) 8200-8210) (Year: 2018).
[cited by applicant]
Zuo X et al., Hepatology, 69 (5), 2031-2047 (Year: 2019).
[cited by applicant]